EGFR and non-small cell lung carcinoma: Due to drug resistance, the treatment of advanced NSCLC using targeted therapies, such as inhibitors or antagonists of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase, can be challenging [2].